CtBP also by binding with p19Arf can inhibit the invasion of hepatocellular carcinoma cells [43] and decrease the sensitivity of breast cancer cells to mechanistically diverse cancer chemotherapeutic agents via p53-dependent and -independent roles [44]. This evidence concerns the gene TP53 and hepatocellular carcinoma.